Gonc E Nazli, Kandemir Nurgun, Kinik Sibel T
Department of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Horm Res. 2003;60(4):191-7. doi: 10.1159/000073232.
To discover the value of low-dose (LDAT) and standard-dose ACTH tests (SDAT) as compared with the metyrapone test in the diagnosis of secondary adrenal insufficiency.
LDAT (0.5 microg/m2), SDAT (250 microg/m2) and overnight metyrapone (30 mg/kg) tests were carried out in 29 patients with suspected adrenal insufficiency. LDAT and SDAT were also performed in 36 control subjects.
18 of 29 patients were grouped in the adrenal-sufficient (AS) group and 11 of 29 patients in the adrenal-deficient (AD) group according to the metyrapone test results. The control group had significantly higher cortisol responses than the AS and AD groups during LDAT. The control group had similar cortisol responses to the AS group but higher cortisol responses than the AD group during SDAT. The AS group was divided into 2 subgroups: AS patients with multiple pituitary hormone deficiencies (AS-multiple) and AS patients with idiopathic growth hormone deficiencies (AS-isolated). The AS-multiple group had statistically lower cortisol responses than the control group during LDAT. Receiver-operating characteristics analysis revealed that the cortisol cutoff value in LDAT was 19.8 microg/dl (100% sensitivity, 89% specificity) and 30.4 microg/dl in SDAT (82% sensitivity, 78% specificity).
LDAT is capable of identifying patients with adrenal insufficiency more effectively than SDAT. The cortisol cutoff value in LDAT was calculated as 19.8 microg/dl with 100% sensitivity. AS patients with multiple pituitary hormone deficiencies had lower cortisol responses to LDAT than the control group implying that these patients might have a lower cortisol secretory capacity than healthy subjects.
比较低剂量(LDAT)和标准剂量促肾上腺皮质激素试验(SDAT)与甲吡酮试验在继发性肾上腺功能不全诊断中的价值。
对29例疑似肾上腺功能不全的患者进行了LDAT(0.5微克/平方米)、SDAT(250微克/平方米)和过夜甲吡酮(30毫克/千克)试验。还对36名对照受试者进行了LDAT和SDAT。
根据甲吡酮试验结果,29例患者中有18例被归为肾上腺功能正常(AS)组,29例患者中有11例被归为肾上腺功能不全(AD)组。在LDAT期间,对照组的皮质醇反应明显高于AS组和AD组。在SDAT期间,对照组的皮质醇反应与AS组相似,但高于AD组。AS组分为2个亚组:患有多种垂体激素缺乏症的AS患者(AS-多种)和患有特发性生长激素缺乏症的AS患者(AS-孤立)。在LDAT期间,AS-多种组的皮质醇反应在统计学上低于对照组。受试者操作特征分析显示,LDAT中皮质醇临界值为19.8微克/分升(敏感性100%,特异性89%),SDAT中为30.4微克/分升(敏感性82%,特异性78%)。
LDAT比SDAT能更有效地识别肾上腺功能不全患者。LDAT中皮质醇临界值计算为19.8微克/分升,敏感性为100%。患有多种垂体激素缺乏症的AS患者对LDAT的皮质醇反应低于对照组,这意味着这些患者的皮质醇分泌能力可能低于健康受试者。